CLBS16

Unassigned

New Medicines

Microvascular angina

Information

Advanced therapy medicinal product (ATMP)
Caladrius
Caladrius

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

CD34+ cell therapy
The prevalence of microvascular angina is estimated to be up to 30% of stable angina patients with non-obstructive coronary arteries. 19% of women presenting with acute coronary syndrome, 30% of women presenting with unstable angina, 9.1% of women with non-ST-elevation myocardial infarction and 10% of women with ST-elevation myocardial infarction were determined to have normal or non-obstructive coronary arteries using coronary angiography [1].
Microvascular angina
Intracoronary